Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


What Will Happen When Rebates Go Away? Look At Authorized Generics

Executive Summary

Recent launches by Lilly, Amgen and Gilead suggest list prices may decrease with the HHS proposal to disrupt the rebate system, but not as low as current net prices after rebates, according to pharmacy benefit experts.

You may also be interested in...

HHS Importation Plan Builds On Use Of Authorized Generics To Lower US List Prices

Plan envisions manufacturers, acting under FDA guidance, will import their own drugs and introduce them in the US under a new national drug code at a lower list price.

One More Score: CBO Projects HHS Rebate Proposal Would Boost Part D Spending $170bn

HHS downplays latest attempt to predict “complex behavior changes to a broken system.”

Same Drug, Two Versions And Prices, This Time For Lilly's Humalog

Lilly will launch an authorized generic version of Humalog at a 50% discount to the brand to assist patients without insurance or a high deductible, who don't benefit from rebates.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts